Invest in the new standard of care in medical vein treatments
Varicose veins pose a significant economic burden on the US healthcare system through high treatment costs and lost productivity.
Issuer
Exiteam Acquisition Corp.
(Canadian Special Purpose Acquisition Corp.)
("CSPAC")
Sole purpose to raise capital and complete a Go-Public business combination transaction
with Israel based operating company
$560.00
Min. Investment
$0.56*
Share Price
* Unit includes one common share @ $0.56 and one purchase warrant with term of 2 years to purchase one common share at price of $0.84 per share.
Testimonials
Here's what medical professionals had to say about ScleroSafe™.
Innovation/Vision
Invest in the future of medical vein treatments
VVT Medical specializes in R&D, manufacturing and commercialization of advanced minimally invasive and patented technology for the treatment of a range of vein conditions, from medical indications to aesthetics.
Our solutions are applicable in a variety of outpatient settings, including vein clinics, day care clinics, hospitals and aesthetics centers.
Our focus is on innovation. We have identified unmet market needs and a great opportunity in the fields of medical vein treatments and aesthetics.
Our products are intuitive and aspire to offer the best treatments to physicians and their patients.
Global Prevalence and economic burden of Varicose Veins
30 Million
Affect over 30 million adults in the US
Affects 23% of adults in the US, more prevalent in women and older adults
Costly treatments
Treatment costs for varicose veins complications total over $3 billion annually in the US.
Lost productivity
Varicose veins result in 2 million lost workdays per year in the US.